Allopurinol
- Generic Name
- Allopurinol
- Brand Names
- Aloprim, Zyloprim
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4O
- CAS Number
- 315-30-0
- Unique Ingredient Identifier
- 63CZ7GJN5I
- Background
Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...
- Indication
Allopurinol is indicated in :
1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...
- Associated Conditions
- Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi
- Associated Therapies
- -
Extension Study of ABP-671 in Participants With Gout
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 580
- Registration Number
- NCT06276556
- Locations
- 🇺🇸
Tucson Neuroscience Research, LLC, Tucson, Arizona, United States
🇺🇸New Horizons Research, Palmetto Bay, Florida, United States
🇺🇸DelRicht Research of Gulfport, Gulfport, Mississippi, United States
Open Label PK, PD and DDI of Dotinurad and Allopurinol in Gout Patients With Hyperuricemia
- Conditions
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Urica Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06056570
- Locations
- 🇺🇸
Panax Clinical Research, Miami Lakes, Florida, United States
🇺🇸Clinical Research of West Florida, Clearwater, Florida, United States
🇺🇸Endeavor Clinical Trials, San Antonio, Texas, United States
Allopurinol Improves Heart Function in African Americans With Resistant Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 50
- Registration Number
- NCT05888233
- Locations
- 🇺🇸
Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama, United States
Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-08-15
- Target Recruit Count
- 580
- Registration Number
- NCT05818085
- Locations
- 🇺🇸
Annapolis Internal Medicine/CCT Research, Annapolis, Maryland, United States
🇺🇸Bioclinical Research Alliance, Miami, Florida, United States
🇺🇸A & D Doctor Center, Miami, Florida, United States
Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- InventisBio Co., Ltd
- Target Recruit Count
- 80
- Registration Number
- NCT05665699
- Locations
- 🇺🇸
Site Center, Bellevue, Washington, United States
🇺🇸Study Center, Morgantown, West Virginia, United States
Effect of Allopurinol on Markers of Mineral and Bone Metabolism
- Conditions
- Interventions
- First Posted Date
- 2022-11-01
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- University of Sao Paulo General Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT05601271
- Locations
- 🇧🇷
Hospital das Clinicas HCFMUSP, São Paulo, SP, Brazil
Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- LG Chem
- Target Recruit Count
- 2542
- Registration Number
- NCT05586971
- Locations
- 🇺🇸
Meridian Clinical Research, LLC, Portsmouth, Virginia, United States
🇺🇸PCCR Solutions, Colleyville, Texas, United States
🇺🇸DFW Clinical Research, Dallas, Texas, United States
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT05536349
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)
- Conditions
- Interventions
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 17
- Registration Number
- NCT05049863
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Crossover Clinical Trial, Randomized, Double Blind, Placebo Controlled Trial
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2021-07-30
- Target Recruit Count
- 22
- Registration Number
- NCT04983160
- Locations
- 🇪🇸
Hospital Universitario Reina Sofía de Córdoba, Córdoba, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.